Impact of prospective screening for multiple endocrine neoplasia type 2.
D000307:Adrenal Gland Diseases / Q000517:prevention & control; D000310:Adrenal Gland Neoplasms / Q000517:prevention & control*; D000313:Adrenal Medulla; D000315:Adrenalectomy; D000328:Adult; D002116:Calcitonin / Q000097:blood; D002277:Carcinoma / Q000517:prevention & control*; D002395:Catecholamines / Q000652:urine; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000235:genetics / Q000517:prevention & control*; D010280:Parathyroid Glands / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood; D010375:Pedigree; D010673:Pheochromocytoma / Q000517:prevention & control*; D011446:Prospective Studies; D011863:Radioimmunoassay; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000517:prevention & control*; D013965:Thyroidectomy; D013997:Time Factors
D002395:Catecholamines; D010281:Parathyroid Hormone; D002116:Calcitonin